Showing 4361-4370 of 5627 results for "".
- GenSight Biologics Reports Topline Results From REFLECT Phase 3 Trial, Confirming Lumevoq Efficacyhttps://modernod.com/news/gensight-biologics-reports-topline-results-from-reflect-phase-3-trial-confirming-lumevoq-efficacy/2479336/GenSight Biologics reported key efficacy and safety findings at 1.5 years (78 weeks) post-treatment in the REFLECT phase 3 clinical trial for Lumevoq. The results show better visual acuity improvements from bilateral intravitreal injections of the gene therapy compared to a unilateral injection.<
- Ocular Therapeutix and Mosaic Biosciences Enter into Strategic Discovery Collaboration Targeting the Treatment of Dry AMDhttps://modernod.com/news/ocular-therapeutix-and-mosaic-biosciences-enter-into-strategic-discovery-collaboration-targeting-the-treatment-of-dry-age-related-macular-degeneration/2479331/Ocular Therapeutix entered into a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents aimed at the treatment of dry age-related macular degeneration (AMD). Ocular Therapeutix has agreed to fund the research performed under the collaboration and re
- Recycling of the Eye’s Light Sensors Is Faulty in Progressive Blindness of Older Adults, University of Maryland School of Medicine Researchers Showhttps://modernod.com/news/recycling-of-the-eyes-light-sensors-is-faulty-in-progressive-blindness-of-older-adults-university-of-maryland-school-of-medicine-researchers-show/2479329/With the National Eye Institute reporting that about 11 million older adults in the U.S. endure a condition that leads to progressive blindness, known as age-related macular degeneration, University of Maryland School of Medicine (UMSOM) researchers are starting to understand what goes wrong in t
- Oxurion NV to Focus Resources on Clinical Assets THR-687 and THR-149https://modernod.com/news/oxurion-nv-to-focus-resources-on-clinical-assets-thr-687-and-thr-149/2479325/Oxurion announced a restructuring plan aimed at better aligning resources towards executing its clinical development strategy, including advancing its two novel programs, THR-687 and THR-149, according to a company news release. Following a detailed review of its operations and gr
- Study Finds Recycling of the Eye’s Light Sensors Is Faulty in Progressive Blindness of Older Adultshttps://modernod.com/news/study-finds-recycling-of-the-eyes-light-sensors-is-faulty-in-progressive-blindness-of-older-adults/2479323/With the National Eye Institute reporting that about 11 million older adults in the US endure age-related macular degeneration (AMD), University of Maryland School of Medicine (UMSOM) researchers are starting to understand what goes wrong in the disease, in order to develop new therapies to tre
- Johnson & Johnson Vision Announces Launch of Tecnis Synergy and Tecnis Synergy Toric II PC-IOLs in US and Canadahttps://modernod.com/news/johnson-johnson-vision-announces-launch-of-tecnis-synergy-and-tecnis-synergy-toric-ii-pc-iols-in-us-and-canada/2479320/Johnson & Johnson Vision announced the availability of Tecnis Synergy and Tecnis Synergy Toric II IOLs in the United States and Canada. These next-generation PC-IOLs combine the best of extended depth of focus and multifocal technologies to deliver the widest range of continuous vision and th
- PanOptica Announces Licensing Agreement with Zhaoke Ophthalmology for the Treatment of Neovascular Eye Diseases in China, South Korea, and Southeast Asiahttps://modernod.com/news/panoptica-announces-licensing-agreement-with-zhaoke-ophthalmology-for-the-treatment-of-neovascular-eye-diseases-in-china-south-korea-and-southeast-asia/2479318/PanOptica announced a licensing agreement with Zhaoke Ophthalmology Limited to develop and commercialize PAN-90806, an investigational topical eye drop for the treatment of neovascular eye diseases, including wet age-related macular degeneration (AMD) and diabetic retinopathy, in China, South Kor
- Gemini Therapeutics Announces Data From Ongoing Phase 2a Study in Patients with GA Secondary to Dry AMDhttps://modernod.com/news/gemini-therapeutics-announces-initial-data-from-its-ongoing-phase-2a-study-of-gem103-in-patients-with-geographic-atrophy-secondary-to-dry-amd/2479317/Gemini Therapeutics announced initial data from its phase 2a ReGAtta study of GEM103 as of May 2021 in patients with geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). ReGAtta is a dose escalation trial of GEM103, which is intravitreally administered recombinant huma
- Belkin Laser Appoints Andrew Webb as Chief Commercial Officerhttps://modernod.com/news/belkin-laser-appoints-andrew-webb-as-chief-commercial-officer/2479316/Israel-based medical device company Belkin Laser has announced the appointment of Andrew Webb as Chief Commercial Officer. Under Mr. Webb’s guidance, the company’s commercial and go-to-market strategy will be rolled out in anticipation of a controlled launch in
- ScienceBased Health Announces New Ophthalmology Clinical Advisory Panelhttps://modernod.com/news/sciencebased-health-announces-new-ophthalmology-clinical-advisory-panel/2479314/ScienceBased Health (SBH) announced the formation of its new Ophthalmology Clinical Advisory Panel that will provide insight and recommendations on eye care industry trends and new developments. In addition, it will help guide and support the company’s educational initiatives in the ophthalmology